Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinghong Han

Showing results (1-10 of 143) with videos related to

Pageof 15
Sort By:
Nature Protocols|October 25, 2008
Enzymatic assay for total plasma CysQinghong Han, Robert M Hoffman
Anticancer Research|April 4, 2021
Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral MethioninaseQinghong Han, Robert M Hoffman
Nature Protocols|November 8, 2008
Nonradioactive enzymatic assay for plasma and serum vitamin B(6)Qinghong Han, Robert M Hoffman
In Vivo (Athens, Greece)|June 28, 2021
Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA LevelsQinghong Han, Robert M Hoffman
In Vivo (Athens, Greece)|June 7, 2020
Oral Methioninase for Covid-19 Methionine-restriction TherapyRobert M Hoffman, Qinghong Han
Anticancer Research|May 6, 2020
Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer PatientQinghong Han, Yuying Tan, Robert M Hoffman
Methods in Molecular Biology (Clifton, N.J.)|February 7, 2019
Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?Robert M Hoffman, Qinghong Han, Kei Kawaguchi, et al.
Anticancer Research|January 30, 2022
Methionine Restriction: Ready for Prime Time in the Cancer Clinic?Jun Yamamoto, Qinghong Han, Mark Simon, et al.
In Vivo (Athens, Greece)|August 31, 2023
Rapid Reduction of CEA and Stable Metastasis in an <i>NRAS</i>-mutant Rectal-Cancer Patient Treated With FOLFIRI and Bevacizumab Combined With Oral Recombinant Methioninase and a Low-Methionine Diet Upon Metastatic Recurrence After FOLFIRI and Bevacizumab Treatment AloneYutaro Kubota, Qinghong Han, Sei Morinaga, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 7, 2019
Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in PrimatesRobert M Hoffman, Zhijian Yang, Yuying Tan, et al.
Pageof 15

Showing results (1-10 of 143) with videos related to

Sort By:
Pageof 15
Nature Protocols|October 25, 2008
Enzymatic assay for total plasma CysQinghong Han, Robert M Hoffman
Anticancer Research|April 4, 2021
Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral MethioninaseQinghong Han, Robert M Hoffman
Nature Protocols|November 8, 2008
Nonradioactive enzymatic assay for plasma and serum vitamin B(6)Qinghong Han, Robert M Hoffman
In Vivo (Athens, Greece)|June 28, 2021
Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA LevelsQinghong Han, Robert M Hoffman
In Vivo (Athens, Greece)|June 7, 2020
Oral Methioninase for Covid-19 Methionine-restriction TherapyRobert M Hoffman, Qinghong Han
Anticancer Research|May 6, 2020
Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer PatientQinghong Han, Yuying Tan, Robert M Hoffman
Methods in Molecular Biology (Clifton, N.J.)|February 7, 2019
Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?Robert M Hoffman, Qinghong Han, Kei Kawaguchi, et al.
Anticancer Research|January 30, 2022
Methionine Restriction: Ready for Prime Time in the Cancer Clinic?Jun Yamamoto, Qinghong Han, Mark Simon, et al.
In Vivo (Athens, Greece)|August 31, 2023
Rapid Reduction of CEA and Stable Metastasis in an <i>NRAS</i>-mutant Rectal-Cancer Patient Treated With FOLFIRI and Bevacizumab Combined With Oral Recombinant Methioninase and a Low-Methionine Diet Upon Metastatic Recurrence After FOLFIRI and Bevacizumab Treatment AloneYutaro Kubota, Qinghong Han, Sei Morinaga, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 7, 2019
Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in PrimatesRobert M Hoffman, Zhijian Yang, Yuying Tan, et al.
Pageof 15